Gilead Sciences (GILD)
113.58
+0.00 (0.00%)
NASDAQ · Last Trade: Oct 7th, 4:18 AM EDT
The company stated that under the settlements, no generic entry is expected for Biktarvy in the United States before April 1, 2036.
Via Stocktwits · October 6, 2025
Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until April 2036.
Via Benzinga · October 6, 2025
The appointment is effective immediately, replacing Hans Vestberg who has led Verizon since 2018.
Via Investor's Business Daily · October 6, 2025
The company is well known for its HIV treatment, Biktarvy. Biktarvy accounted for more than two-thirds of Gilead's HIV June-quarter sales.
Via Investor's Business Daily · October 6, 2025
Lupin Gains On FDA Nod For HIV Drug; Technicals Suggest Potential Upside Above ₹2,060stocktwits.com
Via Stocktwits · September 25, 2025
SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks?stocktwits.com
Via Stocktwits · September 11, 2025
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
Via Chartmill · October 6, 2025
Both have crushed the market in 2025.
Via The Motley Fool · October 4, 2025
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.
Via Benzinga · October 2, 2025
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market.
But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.
Via StockStory · October 1, 2025
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by Danish biotech giant Genmab A/S (NASDAQ: GMAB). The all-cash transaction, valued at approximately $8.0 billion, represents
Via MarketMinute · September 29, 2025
As the clock ticks towards the September 30, 2025, funding deadline, the United States federal government finds itself perilously close to another shutdown. Congressional leaders remain deadlocked on a spending bill, with crucial negotiations underway to avert what would be the 15th partial federal government shutdown since 1981. This looming
Via MarketMinute · September 29, 2025
Wall Street’s bearish price targets for the stocks in this article signal serious concerns.
Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Via StockStory · September 29, 2025
Gilead Sciences (GILD) shows strong technicals with a top rating of 9. It's forming a high-quality consolidation pattern, suggesting a potential breakout above $117.42.
Via Chartmill · September 24, 2025
Via Benzinga · September 23, 2025
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Via StockStory · September 23, 2025
Gilead Sciences has been treading water for the past six months, holding steady at $112.78. The stock also fell short of the S&P 500’s 16.5% gain during that period.
Via StockStory · September 16, 2025
The U.S. economy finds itself at a critical juncture, as signals from The Conference Board's Leading Economic Index (LEI) point toward a sustained period of economic weakening. While the LEI's consistent downward trend has historically preceded recessions, The Conference Board maintains a nuanced outlook, forecasting a "significant slowdown" rather
Via MarketMinute · September 15, 2025
As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter.
Via MarketBeat · September 15, 2025
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Monday. Stay informed about the latest market trends.
Via Chartmill · September 15, 2025
Gilead Sciences (GILD) is a strong value investing candidate, trading at a significant discount with high profitability, solid financial health, and positive growth prospects.
Via Chartmill · September 13, 2025
American households are bracing for a significant financial hit as a wave of tariff-induced inflation sweeps across critical consumer goods and services. From the family car to essential baby products, and even the cost of staying healthy, prices are already on an upward trajectory or are poised for substantial hikes.
Via MarketMinute · September 10, 2025